Core Insights - Biotechnology stocks experienced significant movements in after-hours trading, with several companies reporting strong gains driven by positive trial results and strategic announcements [1] Company Performances - Exicure, Inc. (XCUR) saw a substantial increase of 72.61% to $9.20 after announcing positive Phase 2 trial results for burixafor, achieving a primary endpoint success rate of approximately 90% in multiple myeloma patients [2] - Artiva Biotherapeutics, Inc. (ARTV) rose 10.39% to $3.40 despite a regular session decline, with no new updates reported [3] - iBio, Inc. (IBIO) advanced 8.38% to $1.81, following a significant 39.17% increase during regular trading [3] - Cartesian Therapeutics, Inc. (RNAC) increased by 6.55% to $7.16, recovering from a prior decline [4] - Metagenomi, Inc. (MGX) gained 7.18% to $1.94, with plans to present preclinical data at an upcoming conference [5] - BioAtla, Inc. (BCAB) rose 4.81% to $0.85, despite no new updates [6] - ProMIS Neurosciences, Inc. (PMN) climbed 3.02% to $7.85, following a publication related to Alzheimer's disease biomarkers [7] - DiaMedica Therapeutics Inc. (DMAC) increased by 4.77% to $9.18, with no new announcements [8] - Wave Life Sciences Ltd. (WVE) shares surged 4.97% to $19.44 after a significant 147.26% increase during regular trading, linked to a $250 million public offering [9] - Assembly Biosciences, Inc. (ASMB) gained 5.96% to $37.49, reporting positive interim results from Phase 1b studies of HSV inhibitors [10]

Core Insights - Exicure, Inc. announced positive results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and G-CSF for mobilizing hematopoietic progenitor cells in multiple myeloma patients undergoing autologous hematopoietic cell transplantation, with approximately 90% of participants achieving the primary endpoint [1][3][6] Company Overview - Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematologic diseases, with its lead program being burixafor (GPC-100) [10] - Burixafor is a small molecule antagonist of CXCR4, designed to enhance the mobilization of hematopoietic stem cells for autologous stem cell transplant procedures [8] Trial Details - The Phase 2 trial was an open-label, multicenter study involving 19 participants, where 17 achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg [3] - The median time to neutrophil engraftment was 13 days, and the median time to platelet engraftment was 17.5 days, indicating rapid mobilization kinetics [3] Efficacy and Safety - The combination treatment was well tolerated, with no burixafor-related adverse events exceeding Grade 2, demonstrating an excellent safety profile [5][6] - Notably, 84.2% of participants had prior exposure to daratumumab, yet 87.5% of these still achieved the primary endpoint, suggesting the treatment's effectiveness even in challenging cases [4][6] Future Applications - Burixafor is being considered for other diseases requiring improved stem cell mobilization, including sickle cell disease and acute myeloid leukemia, indicating its potential for broader therapeutic applications [9][10]

Financial Performance - Total revenue for the nine months ended September 30, 2025, was $500,000, compared to no revenue for the same period in 2024[21]. - The net loss for the three months ended September 30, 2025, was $2,437,000, compared to a net loss of $1,091,000 for the same period in 2024, indicating an increase in loss of approximately 123.8%[25]. - As of September 30, 2025, Exicure, Inc. reported a net loss of $2,048,000, compared to a net loss of $2,520,000 for the same period in 2024, indicating an 18.7% improvement in losses year-over-year[34]. - The company reported a basic and diluted loss per common share of $0.39 for the three months ended September 30, 2025, compared to $0.57 for the same period in 2024[21]. - The Company reported total revenues of $0 for the three months ended September 30, 2025, compared to $50,000 for the same period in 2024[104]. - The Company incurred a total operating expense of $2,391,000 for the three months ended September 30, 2025, compared to $2,572,000 for the same period in 2024[104]. Assets and Liabilities - Total current assets decreased from $13,673,000 on December 31, 2024, to $5,439,000 on September 30, 2025, representing a decline of approximately 60.2%[19]. - Cash and cash equivalents decreased from $12,508,000 on December 31, 2024, to $4,438,000 on September 30, 2025, a decline of about 64.6%[19]. - The accumulated deficit increased from $199,264,000 on December 31, 2024, to $201,312,000 on September 30, 2025, reflecting a rise of approximately 1%[19]. - Total liabilities increased slightly from $8,284,000 on December 31, 2024, to $8,340,000 on September 30, 2025[19]. - As of September 30, 2025, total financial liabilities measured at fair value are $5,787,000, all classified as Level 3 liabilities[115]. Cash Flow and Operating Activities - The company experienced a net cash used in operating activities of $7,408,000 for the nine months ended September 30, 2025, significantly higher than the $2,065,000 used in the same period of 2024[34]. - Cash, cash equivalents, and restricted cash at the end of the period were $4,438,000, down from $12,508,000 at the beginning of the period, reflecting a decrease of 64.6%[34]. - The company expects to incur significant expenses and negative cash flows for the foreseeable future, necessitating additional funding[51]. Strategic Alternatives and Uncertainties - The company has substantial uncertainties regarding its ability to raise additional capital needed to fund operations and strategic alternatives due to a lack of revenue source[12]. - The company is exploring strategic alternatives to maximize stockholder value, which may involve unexpected costs and liabilities[12]. - As of September 30, 2025, Exicure's management expressed substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations[50]. Acquisitions and Collaborations - Exicure acquired GPCR Therapeutics USA Inc. for $1,600,000, which included the purchase of 6,000,000 common shares[40]. - The company entered into a License and Collaboration Agreement with GPCR, requiring milestone payments and recurring royalty payments based on future sales[41]. - GPCR USA is conducting a Phase 2 clinical trial involving GPC-100 for blood cancer patients, with results expected to be announced in Q4 2025[42]. - The total purchase price for the acquisition of GPCR USA was $7,881,000, which included $1,635,000 in cash, $500,000 in equity consideration, and $5,246,000 in fair value of contingent consideration[67]. - The assets acquired included cash and cash equivalents of $45,000, property and equipment valued at $626,000, and intangible assets worth $3,784,000, totaling $9,291,000[67]. - Goodwill recorded from the acquisition amounted to $3,340,000, reflecting the excess of the purchase price over the net fair value of identifiable assets acquired[67]. Legal Proceedings and Settlements - The settlement of the securities class action lawsuit includes a payment of $5,625,000, fully covered by insurance[118]. - The Company is involved in multiple legal proceedings, including derivative lawsuits and a breach of contract claim, which may impact management resources[123]. - The Company recorded an accrual of approximately $1,100,000 for the unsatisfied portion of its self-insured retainer as of September 30, 2024[119]. Accounting and Financial Reporting - The company plans to adopt the new accounting standard ASU 2024-03 for the fiscal year 2027, which will require additional disclosures about specific expense categories[63]. - The company’s annual goodwill impairment review is performed on December 31 each year, assessing qualitative factors to determine potential impairment[61]. - The effective tax rate for the Company was 0% for the nine months ended September 30, 2025, due to generated tax losses and a full valuation allowance against deferred tax assets[107].

Financial Performance - The net loss for Q3 2025 was $2.4 million, compared to a net loss of $1.1 million in Q3 2024, marking an increase in net loss of 118.2%[7] - Total revenue for the nine months ended September 30, 2025, was $0, compared to $500,000 for the same period in 2024, indicating a significant decline in revenue[16] - The company reported total operating expenses of $2.4 million for Q3 2025, a decrease of 7% from $2.6 million in Q3 2024[16] - The company recognized a loss of $246,000 related to the change in the fair value of its contingent liability during Q3 2025[6] Cash Position - Cash and cash equivalents decreased to $4.4 million as of September 30, 2025, down from $12.5 million as of December 31, 2024, representing a decline of 64.8%[3] - Management indicated that existing cash and cash equivalents are insufficient to fund operations, necessitating substantial additional financing in the short term[8] Expenses - Research and development expenses for Q3 2025 were $0.9 million, compared to $0 for Q3 2024, indicating the company began incurring R&D costs following the acquisition of GPCR Therapeutics USA Inc.[4] - General and administrative expenses increased to $1.5 million in Q3 2025 from $1.4 million in Q3 2024, reflecting an increase of 7.1% primarily due to costs associated with the GPCR USA acquisition[5] Assets and Equity - The company’s total assets as of September 30, 2025, were $15.3 million, a slight increase from $15.1 million as of December 31, 2024[14] - Stockholders' equity increased to $6.9 million as of September 30, 2025, from $6.8 million as of December 31, 2024, reflecting a growth of 2.3%[14]

Core Insights - Exicure, Inc. reported a net loss of $2.4 million for Q3 2025, an increase from a net loss of $1.1 million in Q3 2024, primarily due to increased operating expenses following the acquisition of GPCR Therapeutics USA Inc. [6][8] Financial Performance - Cash and cash equivalents decreased to $4.4 million as of September 30, 2025, down from $12.5 million as of December 31, 2024 [2]. - Research and development expenses for Q3 2025 were $0.9 million, compared to $0 for Q3 2024, reflecting the costs incurred after acquiring GPCR USA [3]. - General and administrative expenses rose to $1.5 million in Q3 2025 from $1.4 million in Q3 2024, largely due to additional costs from the GPCR USA acquisition [4]. - The company recognized a loss of $246,000 related to changes in the fair value of its contingent liability, while also recording a gain of $155,000 from satisfying its self-insured retainer [5]. Balance Sheet Highlights - Total assets as of September 30, 2025, were $15.3 million, slightly up from $15.1 million as of December 31, 2024 [12][13]. - Current liabilities decreased to $2.8 million from $3.1 million over the same period [12]. - Stockholders' equity increased to $6.9 million as of September 30, 2025, compared to $6.8 million at the end of 2024 [13]. Strategic Outlook - The company is exploring strategic alternatives to maximize stockholder value following its restructuring and the acquisition of GPCR USA, which focuses on developing therapeutics for hematologic diseases [8]. - Management expressed concerns that the current cash position is insufficient to fund ongoing operations, indicating a need for substantial additional financing in the short term [7].

Core Insights - Exicure, Inc. announced that results from its Phase 2 study of burixafor will be presented at the 67th ASH Annual Meeting in December 2025 [1][2] - Burixafor is a small molecule CXCR4 antagonist aimed at mobilizing hematopoietic progenitor cells for transplantation in multiple myeloma patients [2][5] Study Details - The Phase 2 trial (NCT05561751) is an open-label, multicenter study assessing burixafor in patients undergoing autologous hematopoietic cell transplantation [2][4] - The combination of burixafor, G-CSF, and propranolol showed an excellent safety profile, with 18 out of 19 patients proceeding to transplantation [3][4] Presentation Information - The oral presentation will take place on December 8, 2025, at 5:45-6:00pm EST, focusing on the safety and efficacy of burixafor in mobilizing hematopoietic progenitor cells [4] Product Overview - Burixafor (GPC-100) is designed to enhance the mobilization of hematopoietic stem cells from the bone marrow into peripheral blood for autologous stem cell transplant procedures [5] - The drug is also being explored for use in other conditions such as sickle cell disease and acute myeloid leukemia [5][6] Company Background - Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematologic diseases, with burixafor as its lead program [6]

Core Insights - Exicure, Inc. announced that results from its Phase 2 study of burixafor will be presented at the 67th ASH Annual Meeting in December 2025 [1][2] - Burixafor is a small molecule CXCR4 antagonist aimed at mobilizing hematopoietic progenitor cells for transplantation in multiple myeloma patients [2][5] Study Details - The Phase 2 trial (NCT05561751) is an open-label, multicenter study assessing burixafor in patients undergoing autologous hematopoietic cell transplantation [2][4] - The combination of burixafor, G-CSF, and propranolol showed an excellent safety profile, with 18 out of 19 patients proceeding to transplantation [3][4] Presentation Information - The oral presentation will take place on December 8, 2025, at 5:45-6:00pm EST, featuring Dr. Jack Khouri as the presenter [4] Product Information - Burixafor (GPC-100) is designed to enhance the mobilization of hematopoietic stem cells from the bone marrow into peripheral blood for autologous stem cell transplant procedures [5] - The drug is also being explored for use in other diseases, including sickle cell disease and acute myeloid leukemia [5][6] Company Overview - Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematologic diseases, with burixafor as its lead program [6]

Core Insights - Exicure, Inc. is advancing its lead program, burixafor (GPC-100), with a Phase 2 trial in multiple myeloma nearing key clinical readout and plans for expansion into sickle cell disease and acute myeloid leukemia [1][2] Phase 2 Trial in Multiple Myeloma - The ongoing Phase 2 study (NCT05561751) is a randomized, open-label, multicenter trial evaluating burixafor as a CXCR4 antagonist in autologous stem cell transplant for multiple myeloma [2][3] - Interim results show 100% of patients (10/10) achieved the primary endpoint of successful CD34+ stem cell mobilization, including those previously treated with daratumumab [3] - Burixafor demonstrates faster mobilization kinetics and a well-tolerated safety profile, allowing same-day administration of the mobilizing agent and leukapheresis, unlike FDA-approved agents requiring overnight pre-treatment [3] Upcoming Milestones - The final patient completed their last study visit in August, and the clinical database is locked, with topline data expected in Q4 2025 [4] - A full data publication from the ongoing Phase 2 trial is anticipated in 2026, alongside a publication from a previous Phase 2 study currently under peer review [5] Expansion into New Indications - Exicure is preparing to expand burixafor into sickle cell disease and acute myeloid leukemia (AML) [6][11] - Discussions are ongoing with key clinicians for an investigator-sponsored trial in sickle cell disease to improve stem cell mobilization during gene editing and autologous transplant [7] - A Phase 1 chemosensitization study in AML is planned, leveraging burixafor's ability to mobilize tumor cells from bone marrow niches to enhance chemotherapy efficacy [7] Leadership Appointments - New leadership appointments include Josephine (Pina) Cardarelli, Ph.D. as President and Chief Scientific Officer, bringing extensive drug development experience [7][8] - Niña Caculitan, Ph.D. has been appointed Head of Clinical, overseeing various clinical development activities [9] - Devki Sukhtankar, Ph.D. joins as Head of Preclinical Research and Translational Medicine, focusing on integrating clinical data and advancing the pipeline [10]

Group 1: Modular Medical Inc. (MODD) - Modular Medical Inc. experienced a significant stock price increase of 30.68% to $0.9150 after completing a clinical study for its MODD1 insulin pump, which aims to simplify diabetes management [1] - The company plans to submit its Pivot pump product to the FDA for clearance in October 2025 [1] - Insider activity has been notable, with executives purchasing over $500,000 worth of shares, contributing to heightened trading volume of over 4.5 million shares, significantly above the average of around 200,000 [2] Group 2: Galectin Therapeutics Inc. (GALT) - Galectin Therapeutics Inc. saw its stock rise over 14% to $6.78, continuing a remarkable year-to-date gain of over 360% [3] - The company reached a new 52-week high of $5.99 during intraday trading on September 11, 2025 [3] - CEO Joel Lewis indicated ongoing analysis of additional biomarkers for their lead candidate, belapectin, which is designed to treat MASH cirrhosis and portal hypertension [4] Group 3: Exicure Inc. (XCUR) - Exicure Inc. shares rose 11.11% to $4.00, despite no new company-specific news, indicating speculative interest or technical momentum [5] - The company reported a second-quarter net loss of $2.6 million, wider than the $0.6 million loss in Q2 of 2024, primarily due to higher operating expenses from the acquisition of GPCR USA [6] - Exicure is pursuing new clinical directions, including a completed Phase 2 study of GPC-100 for stem cell mobilization in multiple myeloma patients [6] Group 4: PepGen Inc. (PEPG) - PepGen Inc. rebounded 6.67% to $1.44 after a previous decline, with the movement likely driven by technical factors or speculative interest [6] - The company has shifted focus to PGN-EDODM1 for treating myotonic dystrophy type 1 (DM1) after discontinuing its Duchenne muscular dystrophy program [7] - The FREEDOM-DM1 trial is currently underway, with topline data expected in early Q4 2025, which is considered a key near-term catalyst [8] Group 5: BioSig Technologies Inc. (BSGM) - BioSig Technologies Inc. closed at $6.10 with a sharp gain of 37.08%, followed by a 4.09% rise in after-hours trading to $6.35 [8] - The company has officially rebranded as Streamex Corp., effective September 12, 2025, and will trade under the new ticker symbol "STEX" [8] - The rebranding follows a merger with Streamex Exchange Corp., marking a strategic pivot towards real-world asset tokenization, including an exclusive partnership with Monetary Metals for tokenized, yield-bearing gold products [9]

Financial Performance - Total revenue for the six months ended June 30, 2025, was $0, down from $500,000 in the same period of 2024[22] - Operating expenses for the three months ended June 30, 2025, were $2,509,000, compared to $1,235,000 for the same period in 2024, reflecting a 103% increase[22] - Net loss for the three months ended June 30, 2025, was $2,621,000, compared to a net loss of $600,000 for the same period in 2024[22] - The company reported a comprehensive loss of $2,520,000 for the three months ended June 30, 2025[24] - As of June 30, 2025, Exicure, Inc. reported a net income of $389,000, a significant improvement compared to a net loss of $1,429,000 for the same period in 2024[33] - The company experienced a net cash used in operating activities of $3,880,000 for the six months ended June 30, 2025, compared to $1,616,000 for the same period in 2024, indicating increased cash outflow[33] - The Company reported total revenues of $0 for the three months ended June 30, 2025, compared to $50,000 for the same period in 2024[101] - The Company incurred a net loss of $2,621,000 for the three months ended June 30, 2025, compared to a net loss of $600,000 for the same period in 2024[105] Assets and Liabilities - Total assets increased to $18,738,000 as of June 30, 2025, compared to $15,056,000 on December 31, 2024, representing a 24% increase[20] - Cash and cash equivalents decreased to $7,858,000 from $12,508,000, a decline of 37%[20] - Accumulated deficit increased to $198,875,000 as of June 30, 2025, from $199,264,000 on December 31, 2024[20] - Stockholders' equity rose to $8,863,000 as of June 30, 2025, up from $6,772,000 at the end of 2024, marking a 31% increase[20] - Exicure's cash, cash equivalents, and restricted cash decreased to $7,858,000 by the end of June 2025, down from $12,508,000 at the beginning of the period[33] - The total purchase price consideration for the acquisition of GPCR USA was $7,881,000, which included $1,635,000 in cash, $500,000 in equity consideration, and $5,246,000 in fair value of contingent consideration[64] - The liabilities assumed during the acquisition amounted to $1,410,000, which included accounts payable of $606,000 and accrued expenses of $92,000[67] Research and Development - Research and development expenses for the six months ended June 30, 2025, totaled $1,743,000, with no expenses reported in the same period of 2024[22] - Research and development expenses for the six months ended June 30, 2025, were $1,743,000, while general and administrative expenses were $3,731,000, compared to $0 and $2,570,000, respectively, for the same period in 2024[101] - GPCR USA is conducting a Phase 2 clinical trial involving GPC-100 for blood cancer patients, with results expected to be announced in Q4 2025[41] Strategic Alternatives and Uncertainties - The company has substantial uncertainties regarding its ability to raise additional capital needed to fund operations and strategic alternatives[13] - The company is exploring strategic alternatives, including private company acquisitions and raising additional capital, to maximize stockholder value[38] - As of June 30, 2025, Exicure's management expressed substantial doubt about the company's ability to continue as a going concern without additional financing[51] Acquisitions and Agreements - The company acquired GPCR Therapeutics USA Inc. for $1,600,000, which included the purchase of 6,000,000 common shares[39] - Exicure entered into a License and Collaboration Agreement with GPCR, requiring an initial payment of $500,000 and milestone payments based on clinical trial achievements[40] - Goodwill recorded from the acquisition was $3,340,000, representing the excess of the purchase price over the net fair value of identifiable assets acquired[59] Legal and Compliance - A settlement of $5,625 million was approved in a securities class action lawsuit, fully covered by insurance[112] - The Company is involved in ongoing litigation, including a complaint from a former employee, which is currently in the discovery phase[118] - The Company accrued $411,000 in penalties due to not filing a registration statement by the Filing Deadline, as per the Registration Rights Agreements[96] Shareholder Information - The weighted-average basic common shares outstanding increased to 6,317,744 as of June 30, 2025, from 1,730,242 as of June 30, 2024[105] - As of June 30, 2025, the Company had 6,317,793 shares of Common Stock issued and outstanding, an increase from 6,026,841 shares as of December 31, 2024[87] - The Company executed two Debt for Equity Exchange Agreements on September 12, 2024, converting $300,000 and $700,000 of debt into 101,991 and 237,223 shares of Common Stock, respectively[85] - The Company entered into multiple Common Stock Purchase Agreements, including a sale of 2,900,000 shares to HiTron for $8,700,000 at $3.00 per share[90] - The Company had authorized 200,000,000 shares of Common Stock, with no preferred stock issued or outstanding as of June 30, 2025[86] Tax and Financial Reporting - The effective tax rate for the Company was 0% for the six months ended June 30, 2025, due to generated tax losses and a full valuation allowance against deferred tax assets[102] - The company has not yet adopted the new income tax disclosure standard (ASU 2023-09), which will be effective for fiscal years beginning after December 15, 2024[63] - The company plans to adopt the new comprehensive income reporting standard (ASU 2024-03) when it becomes effective in the fiscal year 2027[61] Miscellaneous - The company recorded depreciation and amortization expense of $132,000 for the six months ended June 30, 2025, compared to $14,000 for the same period in 2024[69] - The company’s total lease costs for the six months ended June 30, 2025, were $282,000, a decrease from $308,000 in the same period of 2024[79] - The Company has entered into a consulting agreement with Paul Kang, with payments of $12.5 million monthly starting February 2025[121] - The Company recorded an accrual of approximately $1,100 million for the unsatisfied portion of its self-insured retainer as of September 30, 2024[115]